EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Autologous gene therapy for hemoglobinopathies: From bench to patient’s bedside

Franco Locatelli, Marina Cavazzana, Haydar Frangoul, Josu de la Fuente, Mattia Algeri, Roland Meisel

Molecular Therapy · 2024

DOI: 10.1016/j.ymthe.2024.03.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2024. Verfasst von Franco Locatelli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Haematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, 00165 Rome, Italy; Catholic Universit…. Hauptthemen laut MEDLINE: Genetic Therapy, Hemoglobinopathies. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences, Swedish Orphan Biovitrum, Vertex Pharmaceuticals Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, a growing number of clinical trials have been initiated to evaluate gene therapy approaches for the treatment of patients with transfusion-dependent β-thalassemia and sickle cell disease (SCD). Therapeutic modalities being assessed in these trials utilize different molecular techniques, including lentiviral vectors to add functional copies of the gene encoding the hemoglobin β subunit in defective cells and CRISPR-Cas9, transcription activator-like effector protein nuclease, and zinc finger nuclease gene editing strategies to either directly address the underlying genetic cause of disease or induce fetal hemoglobin production by gene disruption. Here, we review the mechanisms of action of these various gene addition and gene editing approaches and describe the status of clinical trials designed to evaluate the potentially for these approaches to provide one-time functional cures to patients with transfusion-dependent β-thalassemia and SCD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyHemoglobinopathiesAnimalsHumansAnemia, Sickle Cellbeta-ThalassemiaClinical Trials as TopicCRISPR-Cas SystemsGene EditingGenetic VectorsLentivirus

Stichwörter der Autor:innen

CRISPR-Cas9gene additiongene editinggene therapysickle cell diseaseviral vectorsβ-thalassemia

Autor:innen und Institutionen

  • Department of Pediatric Haematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, 00165 Rome, Italy; Catholic University of the Sacred Heart, 00168 Rome, Italy. Electronic address: franco.l…
  • Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University of Paris, 75006 Paris, France.
  • Sarah Cannon Center for Blood Cancer at The Children's Hospital at TriStar Centennial, Nashville, TN 37203, USA.
  • Imperial College Healthcare NHS Trust, St Mary's Hospital, London W21NY, UK.
  • Department of Pediatric Haematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, 00165 Rome, Italy; Department of Health Sciences, Magna Graecia University, 88100 Catanzaro, Italy.
  • Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, 40225 Duesseldorf, Germany.

Förderung

  • Gilead Sciences
  • Swedish Orphan Biovitrum
  • Vertex Pharmaceuticals Incorporated

Zitieren

APA

Locatelli, F., Cavazzana, M., Frangoul, H., Fuente, J., Algeri, M., & Meisel, R. (2024). Autologous gene therapy for hemoglobinopathies: From bench to patient’s bedside. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.03.005

Vancouver

Locatelli F, Cavazzana M, Frangoul H, Fuente J, Algeri M, Meisel R. Autologous gene therapy for hemoglobinopathies: From bench to patient’s bedside. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.03.005

BibTeX
@article{Locatelli2024,
  author = {Locatelli, Franco and Cavazzana, Marina and Frangoul, Haydar and Fuente, Josu de la and Algeri, Mattia and Meisel, Roland},
  title = {Autologous gene therapy for hemoglobinopathies: From bench to patient’s bedside},
  journal = {Molecular Therapy},
  year = {2024},
  doi = {10.1016/j.ymthe.2024.03.005}
}
Kostenlos starten →